Articles tagged with Parkinsons Disease
Aryn Gittis, a Carnegie Mellon University neuroscientist, has been recognized for her creativity and originality in research. She discovered a class of neurons that restored movement in a mouse model for Parkinson's disease when targeted with optogenetics.
A recent study suggests that drinking coffee may protect against both Alzheimer's and Parkinson's diseases. The research found that phenylindanes, compounds present in dark roasted coffee, inhibit the formation of beta amyloid and tau protein fragments, which are common in these diseases.
New research presents promising results from preclinical studies using gene therapy to treat amyotrophic lateral sclerosis, Parkinson's disease, and other neurological disorders. Gene therapy has been successfully used to slow disease progression and improve symptoms in mouse models.
A study published in Science identifies Parthanatos as a key driver of nerve cell degradation in Parkinson's disease. The researchers found that blocking a protein called PARP1 can rescue cells from death, suggesting new targets for drugs to interrupt the disease progression.
A study published in Science Translational Medicine found that removing the appendix early in life can lower the risk of developing Parkinson's disease. The appendix acts as a reservoir for disease-associated proteins, and appendectomy delays disease progression by an average of 3.6 years.
Researchers at The University of Queensland have developed a promising new therapy using the small molecule MCC950, which blocks NLRP3 activation and prevents brain cell loss in Parkinson's patients. The therapy shows marked improvement in motor function and may offer an alternative approach to current treatments.
A recent study published in Neurology suggests that when Parkinson's disease does not affect thinking skills early on, life span is not affected. The study found people with problems with memory and thinking skills were more likely to die during the study.
Researchers have developed a novel strategy to measure material properties of the cell nucleus and its components using naturally occurring cellular dynamics. The study shows that human nucleoli behave like liquid droplets, which can influence disease progression, such as Alzheimer's and Parkinson's disease.
Researchers at Lehigh University identify fruit fly protein Scarlet as a key to preventing age-dependent loss of dopaminergic neurons in Parkinson's disease. The study found that Scarlet has a neuroprotective role in a model of the disease, suggesting potential for future treatments.
Researchers tracked over 12,000 participants to estimate the lifetime risk of dementia, Parkinson's disease, and stroke. Preventive strategies could delay onset and reduce lifetime risk by 20-50% in theory, particularly for those aged 85+.
A team of Canadian scientists discovered a French-Canadian founder mutation gene linked to synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease and dementia. The GBA mutation increases the risk of developing these diseases, particularly in people with other mutations.
Researchers evaluated the safety of pimavanserin for treating Parkinson's disease psychosis, finding a lower mortality risk compared to quetiapine or combination therapy. The study provides reassurance for clinicians and families but highlights the need for further research on disease severity and cause of death.
Researchers created a way to measure different types of fear of falling (FOF) in Parkinson's patients, highlighting the importance of cognitive function. The study aims to improve treatment and quality of life for patients with FOF.
A team of scientists has identified a molecule called SynuClean-D that can inhibit the aggregation of alpha-synuclein protein, a key contributor to Parkinson's disease. By administering SynuClean-D to Caenorhabditis elegans worms, researchers were able to reduce alpha-synuclein aggregations and prevent neural degeneration.
Researchers advocate for a systems biology approach to better understand Parkinson's disease, emphasizing the need for modern, human-based technologies to improve treatment outcomes.
A comprehensive study has cataloged over 70,000 novel noncoding RNAs active in dopamine neurons, implicating them in conditions like Parkinson's disease and schizophrenia. The findings suggest that genetic risk variants may affect gene switches in these specialized cells.
Computer simulation models how toxic proteins spread through the brain to reproduce patterns of atrophy associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. The model reveals that biochemistry and connectivity play key roles in mediating disease progression.
Researchers found ADHD patients had a higher risk of developing Parkinson's and Parkinson-like diseases than non-ADHD individuals, especially those prescribed stimulant medications. The study suggests that the long-term health effects of ADHD and its treatment remain understudied.
MIT neuroscientists have developed tiny probes that can measure dopamine levels in the brain for more than a year. The sensors were implanted in animals and found to produce accurate readings for up to 393 days, opening up new possibilities for understanding dopamine's role in diseases such as Parkinson's.
A high-throughput screening study has identified six potent small-molecule inhibitors of α-synuclein aggregation, which could potentially halt Parkinson's disease development. The compounds target the monomeric state of αSN and share a common core structure.
A new €10 million Parkinson's study will implement an integrated care model designed specifically for people with Parkinson's disease across two health hubs in Bath, UK and Nijmegen, Netherlands. The project aims to bridge the gap between fragmented care providers and deliver proactive and integrated care to patients.
Researchers tracked marmosets with Fitbit-like devices to study sleep disturbances, circadian rhythm changes, and cognitive impairment, mirroring Parkinson's non-motor symptoms. The findings provide a valuable animal model for understanding the neuro-circuitry responsible for these complex aspects of the disease.
Researchers developed a modified Nurr1 protein that can enter cells from the outside, showing promise in treating Parkinson's disease. The protein increased tyrosine hydroxylase production, a key enzyme in dopamine synthesis, and protected against neurotoxin-induced cell death.
A novel brain network has been discovered that links chronic pain in Parkinson's disease to a specific region of the brain, including the subthalamic nucleus. This research provides new insights into pain processing and suggests a potential target for pain relief in PD and other neurological diseases.
Researchers found that deep brain stimulation affects different neural pathways for motor and cognitive functions. The treatment shows improved effects on motor control and fewer adverse cognitive effects.
A study of 2.5 million Swedes found that high job demands and low control were associated with increased Parkinson's disease risk. High education level was a moderating factor for men, while low education level exacerbated the risk among women.
A new study has found that the thinning of the retina is linked to the loss of brain cells that produce dopamine, a substance that helps control movement. This discovery may lead to a simple eye scan being used to detect Parkinson's disease in its earliest stages.
Guidelines for discovering Parkinson's biomarkers aim to develop new treatments, focusing on biomarkers within the disease itself. The research emphasizes collaboration and access to biobanks containing thousands of biological samples.
Scientists at Michigan State University have discovered a navigational gene in glass catfish that responds to magnetic waves, which may one day be used to treat Parkinson's and epilepsy. The gene, called the electromagnetic-perceptive gene, can be activated using magnets and has shown promise in controlling movement in mice.
A new study from Rice University links biological markers for cancer-related exhaustion to fatigue in Parkinson's disease, highlighting potential targets for treatment. Researchers found elevated levels of inflammatory biomarkers in patients with Parkinson's who experienced fatigue, similar to those seen in cancer patients.
New research reveals that coral-algal partnerships date back to the Jurassic Period, approximately 160 million years ago. This finding challenges previous assumptions and provides evidence for a more diverse range of algal species worldwide.
A team of scientists found that coral-algal partnerships are older and more diverse than previously thought, with a history dating back to the 'age of dinosaurs.' This relationship has enabled corals to adapt to environmental changes over millions of years.
Researchers at the University of Basel have identified a factor that could support the early detection of neurodegenerative diseases such as Alzheimer's or Parkinson's. FGF21 is induced by cellular stress reactions after disturbances in mitochondria and can be detected prior to neuronal cell death.
A study published in eNeuro found a common neural signature of balance maintenance in the healthy brain, which could be used to assess balance in patients with movement disorders. The researchers used EEG and EMG to record electrical activity from the brain and muscles while participants walked or stood on a narrow beam.
Nir Grossman's temporal interference (TI) approach stimulates deep brain regions without surgery, offering a new treatment option for brain disorders. TI uses multiple electric fields to target specific brain areas, improving spatial resolution and non-invasiveness.
Aryn Gittis' research establishes new therapeutic targets for Parkinson's therapies, using optogenetics to identify a subset of neurons in the globus pallidus that play a critical role in restoring movement. Her findings suggest targeting these cells could repair neural circuit dysfunction in diseases like Parkinson's.
A post hoc analysis of the exenatide-PD trial results showed that patients on exenatide treatment experienced improvements in severity of depression, independent of motor function improvement. Additionally, self-reported apathy and cognition also improved with exenatide.
Ceria nanoparticles selectively remove reactive oxygen species from mitochondria, intracellular and extracellular spaces, improving Parkinson's disease symptoms in mice. Lowering oxidative stress in these compartments is crucial for treating the disease.
Researchers have discovered a new link between gene LLRK2 and Parkinson's disease, suggesting that therapies currently being developed for a small group of patients may benefit everyone with the disease. The study also found that LRRK2 plays a key role in clearing excess alpha-synuclein, a protein associated with Parkinson's.
Researchers developed a sensor to detect early-stage Parkinson's disease from patient breath, achieving 79% sensitivity and 84% specificity. The device detected differences in the exhaled breath of newly diagnosed patients, outperforming diagnostic smell tests and ultrasound scans.
Researchers found that LRRK2 protein activity may contribute to Parkinson's disease development in up to three percent of patients without gene mutations. The study identified LRRK2 as a key player in neurobiological pathways affected by the disease.
A new study finds contact sports associated with an increased risk of Lewy Body Disease (LBD), which can cause Parkinson's disease and dementia. LBD was linked to problems with movement, cognition, depression, sleep, and visual hallucinations, independent of CTE pathology.
Disrupted transportation routes in nerve cells cause Parkinson's disease by destroying synapses and leading to cell death. Researchers identified alpha-synuclein protein as the trigger for these traffic jams.
Researchers explore two approaches to stem cell therapy for Parkinson's disease, one using patient-specific induced pluripotent stem cells and the other utilizing parthenogenetic-derived neural stem cells. The latter approach offers advantages in terms of reduced immunogenicity and evasion of ethical issues surrounding embryos.
Researchers at FAU found that immune cells in Parkinson's patients, specifically T-cells, kill nerve cells producing dopamine. Antibodies blocking Th17 cells offer hope for new treatment methods.
A new method tracks mechanisms causing nerve cell damage in the heart, a previously unappreciated area affected by Parkinson's disease. The research has implications for testing therapies and exploring causes of fatigue, fainting, and falling.
Researchers develop experimental drug NLY01 that slows Parkinson's disease progression in mice by blocking degradation of brain cells and protecting nerve cells. The drug, similar to diabetes treatments, may offer a new treatment option for the progressive disorder.
A Vanderbilt University Medical Center study found that deep brain stimulation (DBS) therapy can slow the progression of tremor in early-stage Parkinson's disease patients. DBS applied in early-stage Parkinson's disease may slow the progression of tremor, a finding that suggests potential for new treatment options.
A new study reveals that half of Parkinson's patients taking dopamine agonist drugs may develop impulse control disorders such as compulsive gambling, shopping, or eating. The five-year cumulative incidence of these disorders is higher in those who have ever taken the medications compared to those who never took them.
The Hong Kong University (HKU) team designed the world's first intra-operative MRI-guided robot for bilateral stereotactic neurosurgery. This innovation enables accurate and safe brain surgery, targeting tiny nucleus structures with minimal damage to surrounding tissue.
Researchers at Baylor College of Medicine identified ceramides as key players in the development of early onset Parkinsonism. The findings propose a mechanism connecting previously identified cellular defects and genes associated with Parkinson's disease, suggesting novel strategies to prevent or treat the condition.
A large study found a strong link between type 2 diabetes and Parkinson's disease, with a 31% greater risk for those with diabetes. Younger people and those with diabetes complications had even higher risks, highlighting potential protective effects of insulin use on the brain.
A study published in Nature Communications has revealed how alpha-synuclein protein clumps cause neurons to die by damaging mitochondria and triggering a channel that leads to cell swelling and bursting. The findings were replicated in human brain cells generated from patient skin cells, providing valuable insights into neurodegeneration.
A team of researchers has identified lipid defects in the brain as the cause of sleep disturbances in Parkinson's disease. Restoring the balance of a key lipid, phosphatidylserine, improves sleep patterns in genetically modified fruit flies and suggests a potential new treatment direction.
A study published in Annals of Clinical and Translational Neurology found that people taking immunosuppressant drugs are less likely to develop Parkinson's disease. Corticosteroids such as prednisone reduced the risk by 20%, while IMDH inhibitors were about one-third less effective.
A new, fully implanted deep brain stimulation device uses real-time brain signals to fine-tune its signaling, reducing side effects and improving symptom control in Parkinson's patients. The adaptive system was shown to be equally effective as traditional stimulation methods in initial short-term studies.
A new three-year trial, led by a geriatrician, aims to determine whether a commonly prescribed dementia drug can prevent falls in people with Parkinson's. The trial, funded by the NIHR Health Technology Assessment programme, will test a cholinesterase inhibitor treatment on 600 patients across UK hospitals.
A new University of Guelph study has discovered that exposure to pesticides like paraquat and maneb increases the risk of developing Parkinson's disease. Low-level pesticide exposure disrupts cells in a way that mimics genetic mutations, drastically increasing disease onset risk.
Researchers have discovered a potential link between tuberculosis and Parkinson's disease, suggesting that drugs designed to treat Parkinson's may also work for TB. The study found that LRRK2 protein prevents immune cells from clearing bacteria, leading to build-up of protein in neurons that disrupts their function.
Patients with inflammatory bowel disease (IBD) are at a 22% higher risk of developing Parkinson's disease compared to non-IBD individuals. Researchers found this association independent of age, gender, and length of follow-up.